The U.S. Food and Drug Administration issued a request on April 15 2026 for Eli Lilly to submit additional safety data on its recently approved obesity drug Foundayo (orforglipron). The request focuses on potential liver injury and cardiovascular events that were flagged during the drug’s clinical program.
Foundayo, Lilly’s first oral GLP‑1 weight‑loss pill, received FDA approval on April 1 2026 under the Commissioner's National Priority Voucher program. The approval made it the second oral GLP‑1 drug approved for weight loss, following Novo Nordisk’s Wegovy pill, and positioned Lilly to compete in a market that values convenience and once‑daily dosing.
On April 16 2026, Lilly released topline results from the Phase III ACHIEVE‑4 trial, showing no hepatic safety signal and demonstrating cardiovascular safety that was non‑inferior to insulin glargine. These data directly address the safety concerns cited in the FDA’s request and provide evidence that the drug’s risk profile is acceptable for post‑approval monitoring.
Lilly’s spokesperson said the post‑approval requirements are routine and that patient safety remains the company’s top priority. The company emphasized that the data requested are part of the standard FDA process for newly approved drugs.
Analysts at BMO Capital Markets described the FDA’s requests as “manageable” and a sign of regulatory conservatism, indicating they do not expect the data request to materially alter Foundayo’s competitive position.
The request could delay further commercialization activities, influence payer coverage decisions, and affect Lilly’s projected revenue from the obesity franchise. The company must submit the requested data to maintain regulatory compliance and sustain market momentum.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.